Sickle Cell Disease
Conditions
Keywords
Crizanlizumab,, sickle cell disease
Brief summary
This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
Detailed description
Patients with a diagnosis of SCD between November 1, 2018 and April 30, 2021 were identified. Among these patients, those who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort. The indexing timeframe allowed for a 1-year lookback period and a minimum of 3 months (3m cohort) of follow-up. A subset of the 3m cohort with 6-months of available (6m cohort) follow-up was performed. The index date was the date of the first crizanlizumab administration. Study period: 01 November 2018 - 30 April 2021 Index period: 01 November 2019 - 31 January 2021 Index date: Date of the first claim for administration of crizanlizumab in the index period
Interventions
OTHERCrizanlizumab
Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* At least 1 claim in IQVIA Patient Centric Medical Claims Database (Dx) with SCD diagnosis (ICD-10 D57.xx, except D57.3) within the study period; * At least 1 claim for administration of crizanlizumab within the index period. Index date was the date of first administration; * At least 1 claim with HCPCs for crizanlizumab (J0791) OR with at least one claim for an unspecified biologic (J3590) on the same day as a claim for SCD (ICD-10 D57.xx, except D57.3) OR with at least one claim with HCPCs C9053; * At least 16 years of age on the index date; * Linkage to the IQVIA Longitudinal Prescription Database (LRx) within the study period; * Stability and eligibility in Dx during the 12 months prior to the index date; * Stability and eligibility in LRx during the 12 months prior to the index date
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients : SCD genotype | Baseline | Number of patients with sickle cell disease genotype were reported. |
| Number of patients by Charlson Comorbidity Index (CCI) score category | Baseline | Severity of comorbidity was categorized into three grades: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores ≥5. |
| Number of patients by comorbidity | Baseline | Number of patients by IQVIA's standard comorbidity list were reported. |
| Number of patients with history of additional SCD-related comorbidities associated with organ damage | Baseline | Number of patients with history of additional SCD-related comorbidities associated with organ damage were reported. |
| Number of patients : History of hydroxyurea use | Baseline | Pre-index treatment history for sickle cell disease was reported. |
| Number of patients : History of L-glutamine use | Baseline | Pre-index treatment history for sickle cell disease was reported. |
| Number of patients : History of Voxelotor use | Baseline | Pre-index treatment history for sickle cell disease was reported. |
| Age | Baseline | Age information was reported. |
| Number of patients: Gender | Baseline | Gender information was reported. |
| Number of patients: Geographic region | Baseline | The following categories were included: Northeast, Midwest, South, West |
| Number of patients: Insurance type | Baseline | When multiple payer types were observed, the following hierarchy was used: Medicare, Commercial, Medicaid, Cash, Unspecifed. When commercially-managed Medicaid was observed, the Medicaid designation was assigned. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of hydroxyurea claims | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
| Proportion of patients with claims for L-glutamine while on crizanlizumab therapy | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
| Number of L-glutamine claims | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
| Proportion of patients with claims for voxelotor while on crizanlizumab therapy | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
| Number of voxelotor claims | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
| Proportion of patients with claims for hydroxyurea while on crizanlizumab therapy | Throughout the follow-up period, approximately 1.5 years | Concomitant SCD treatments after initiating crizanlizumab |
Countries
United States
Outcome results
None listed